
Celastrol promotes apoptosis of breast cancer MDA-MB-231 cells by targeting HSDL2
Acupuncture and Herbal Medicine ›› 2024, Vol. 4 ›› Issue (1) : 92-101.
Celastrol promotes apoptosis of breast cancer MDA-MB-231 cells by targeting HSDL2
Objective: Celastrol is a pentacyclic triterpenoid extracted from the traditional Chinese medicinal herb, Tripterygium wilfordii. This study aims to provide a scientific basis for the rational development and use of celastrol in breast cancer.
Method: A quantitative chemical biology approach was used to investigate the protein targets and molecular mechanisms of celastrol in breast cancer cells.
Results: Low-concentration celastrol exerted an anti-tumor effect by directly binding to hydroxysteroid dehydrogenase-like 2 (HSDL2) and inhibiting its expression. Moreover, the expression of the pro-apoptotic protein, Bcl-2-associated X (BaX), increased, the level of the anti-apoptotic protein, B-cell lymphoma-2 (Bcl-2), decreased, and the rate of apoptosis increased. After the transfection of cells with si-HSDL2, the apoptosis rate was similar to that observed after the administration of celastrol. However, apoptosis was reversed by the overexpression of HSDL2. Furthermore, our mass spectrometry (MS) data indicated a relationship between HSDL2 and the mitogen-activated protein kinase (MAPK) signaling pathway. We also found that the expression of HSDL2 was directly related to the degree of extracellular signal-regulated kinase (ERK) phosphorylation.
Conclusion: Celastrol may promote apoptosis by suppressing the HSDL2/MAPK/ERK signaling pathway.
Activity-based protein profiling / Apoptosis / Celastrol / HSDL2
Activity-based protein profiling / Apoptosis / Celastrol / HSDL2
[[1]] |
Sung H, Ferlay J, Siegel RL, et al.Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021;71(3):209-249.
|
[[2]] |
McGuire S. World Cancer Report 2014. Geneva, Switzerland: World Health Organization, International Agency for Research on Cancer, WHO Press 2015. Adv Nutr 2016;7(2):418-419.
|
[[3]] |
Dhakal R, Noula M, Roupa Z, et al.A scoping review on the status of female breast cancer in Asia with a special focus on Nepal. Breast Cancer (Dove Med Press) 2022;14:229-246.
|
[[4]] |
Dent R, Trudeau M, Pritchard KI, et al.Triple-negative breast cancer: clinical features and recurrence patterns. Clin Cancer Res 2007;13(15 Pt 1):4429-4434.
|
[[5]] |
Mezni E, Behi K, Goncalves A.Immunotherapy and breast cancer: an overview. Curr Opin Oncol 2022;34(5):587-594.
|
[[6]] |
Pace S, Zhang K, Jordan PM, et al.Anti-inflammatory celastrol promotes the switch from leukotriene biosynthesis to the formation of specialized pro-resolving lipid mediators. Pharmacol Res 2021;167:105556.
|
[[7]] |
Liu DD, Luo P, Gu L, et al.Celastrol exerts a neuroprotective effect by directly binding to HMGB1 during cerebral ischemiareperfusion. J Neuroinflammation 2021;18(1):174.
|
[[8]] |
Feng X, Guan D, Auen T, et al.IL1R1 is required for leptin sensitization and the anti-obesity effects of celastrol. Nat Med 2019;25(4):575-582.
|
[[9]] |
Zhu C, Yang J, Zhu Y, et al.Celastrol alleviates comorbid obesity and depression by directly binding to amygdala HnRNPA1 in a mouse model. Clin Transl Med 2021;11(6):e394.
|
[[10]] |
Chen G, Zhu X, Li J, et al.Celastrol inhibits lung cancer growth by triggering histone acetylation and acts synergistically with HDAC inhibitors. Pharmacol Res 2022;185:106487.
|
[[11]] |
Chen X, Zhao Y, Luo W, et al.Celastrol induces ROS-mediated apoptosis by directly targeting peroxiredoxin-2 in gastric cancer cells. Theranostics 2020;10(22):10290-10308.
|
[[12]] |
Kun-Ming C, Chih-Hsien C, Chen-Fang L, et al.Potential anticancer effect of celastrol on hepatocellular carcinoma by suppressing CXCR4-related signal and impeding tumor growth in vivo. Arch Med Res 2020;51(4):297-302.
|
[[13]] |
Zhang J, Wang R, Cheng L, et al.Celastrol inhibits the proliferation, invasion, and migration of human cervical HeLa cancer cells through the downregulation of MMP-2 and MMP-9. J Cell Mol Med 2021;25(11):5335-5338.
|
[[14]] |
Liu Z, Fan M, Xuan X, et al.Celastrol inhibits migration and invasion and enhances the anticancer effects of docetaxel in human triple-negative breast cancer cells. Med Oncol 2022;39(12):189.
|
[[15]] |
You D, Jeong Y, Yoon SY, et al.Celastrol attenuates the inflammatory response by inhibiting IL-1beta expression in triple-negative breast cancer cells. Oncol Rep 2021;45(6):89.
|
[[16]] |
Kim Y, Kang H, Jang SW, et al.Celastrol inhibits breast cancer cell invasion via suppression of NF-κB-mediated matrix metalloproteinase-9 expression. Cell Physiol Biochem 2011;28(2):175-184.
|
[[17]] |
Wang J, Gao L, Lee YM, et al.Target identification in natural and traditional medicines using quantitative chemical proteomic approaches. Pharmacol Ther 2016;162:10-22.
|
[[18]] |
Han A, Xu R, Liu Y, et al.HSDL2 acts as a promoter in pancreatic cancer by regulating cell proliferation and lipid metabolism. Onco Targets Ther 2021;14:435-444.
|
[[19]] |
Kowalik D, Haller F, Adamski J, et al.We determined the functions of the two human orphan SDR enzymes, hydroxysteroid dehydrogenase-like 2 (HSDL2) and short-chain dehydrogenase/ reductase-orphan (SDR-O). J Steroid Biochem Mol Biol 2009;117(4-5):117-124.
|
[[20]] |
Yu Y, Ge X, Wang LS, et al.Abnormalities in hsa-mir-16 and hsa-mir-124 affect mitochondrial function and fatty acid metabolism in tetralogy of Fallot. Comb Chem High Throughput Screen 2023;26(2):373-382.
|
[[21]] |
Dong B, Yang Y, Han A, et al.Ectopic HSDL2 expression is associated with breast cancer cell proliferation and prognosis. Cancer Manag Res 2019;11:6531-6542.
|
[[22]] |
Yang Y, Han A, Wang X, et al.Lipid metabolism regulator human hydroxysteroid dehydrogenase-like 2 (HSDL2) modulates cervical cancer cell proliferation and metastasis. J Cell Mol Med 2021;25(10):4846-4859.
|
[[23]] |
Mi C, Shi H, Ma J, et al.Celastrol induces apoptosis of breast cancer cells and inhibits their invasion via downregulation of MMP- 9. Oncol Rep 2014;32(6):2527-2532.
|
[[24]] |
Liu WB, Wang HL, Chen L, et al.Cucurbitacin E inhibits cellular proliferation and induces apoptosis in melanoma cells by suppressing HSDL2 expression. Chin Med 2022;17(1):28.
|
[[25]] |
Guo YJ, Pan WW, Liu SB, et al.The ERK/MAPK signalling pathway and tumorigenesis. Exp Ther Med 2020;19(3):1997-2007.
|
[[26]] |
Umer M, Naveed M, Alrowais F, et al.Breast cancer detection using convoluted features and ensemble machine learning algorithm. Cancers (Basel) 2022;14(23):6015.
|
[[27]] |
Cosentino K, Garcia-Saez AJ.Mitochondrial alterations during apoptosis. Chem Phys Lipids 2014;181:62-75.
|
[[28]] |
Abdulhussein D, Kanda M, Aamir A, et al.Apoptosis in healthy and diseased eyes and brain. Adv Protein Chem Struct Biol 2021;126:279-306.
|
[[29]] |
Dadsena S, Zollo C, Garcia-Saez AJ.Mechanisms of mitochondrial cell death. Biochem Soc Trans 2021;49(2):663-674.
|
[[30]] |
Tait SW, Green DR.Mitochondria and cell death: outer membrane permeabilization and beyond. Nat Rev Mol Cell Biol 2010;11(9):621-632.
|
[[31]] |
Asl ER, Amini M, Najafi S, et al.Interplay between the MAPK/ ERK signaling pathway and miRNAs: a crucial mechanism regulating cancer cell metabolism and tumor progression. Life Sci 2021;278:119499.
|
[[32]] |
Roskoski R.ERK1/2 MAP kinases: structure, function, and regulation. Pharmacol Res 2012;66(2):105-143.
|
[[33]] |
Ullah R, Yin Q, Snell AH, et al.RAF-MEK-ERK pathway in cancer evolution and treatment. Semin Cancer Biol 2022;85:123-154.
|
[[34]] |
Deng R, Zhang HL, Huang JH, et al.MAPK1/3 kinasedependent ULK1 degradation attenuates mitophagy and promotes bone metastasis in breast cancer. Autophagy 2021;17(10): 3011-3029.
|
[[35]] |
Ramirez-Ardila D, Timmermans AM, Helmijr JA, et al.Increased MAPK1/3 phosphorylation in luminal breast cancer related with PIK3CA hotspot mutations and prognosis. Transl Oncol 2017;10(5):854-866.
|
/
〈 |
|
〉 |